PL3380522T3 - Cząsteczki przeciwciał wobec april i ich zastosowania - Google Patents

Cząsteczki przeciwciał wobec april i ich zastosowania

Info

Publication number: PL3380522T3
Authority: PL; Poland
Prior art keywords: applications; antibody molecules; molecules against; against april; april
Prior art date: 2015-11-25

Application number

PL16810195.4T

Other languages

English (en)

Inventor

James R. Myette

Zachary Holmes Shriver

Karthik Viswanathan

Andrew M. WOLLACOTT

Hedy ADARI-HALL

Boopathy Ramakrishnan

Gregory Babcock

Original Assignee

Visterra, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-11-25

Filing date

2016-11-23

Publication date

2024-03-25

2016-11-23 Application filed by Visterra, Inc. filed Critical Visterra, Inc.

2024-03-25 Publication of PL3380522T3 publication Critical patent/PL3380522T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Mycology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)

PL16810195.4T 2015-11-25 2016-11-23 Cząsteczki przeciwciał wobec april i ich zastosowania PL3380522T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201562259897P	2015-11-25	2015-11-25
US201662313684P	2016-03-25	2016-03-25
US201662399087P	2016-09-23	2016-09-23
US201662422848P	2016-11-16	2016-11-16
PCT/US2016/063518 WO2017091683A1 (en)	2015-11-25	2016-11-23	Antibody molecules to april and uses thereof

Publications (1)

Publication Number	Publication Date
PL3380522T3 true PL3380522T3 (pl)	2024-03-25

Family

ID=57543212

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL16810195.4T PL3380522T3 (pl)	2015-11-25	2016-11-23	Cząsteczki przeciwciał wobec april i ich zastosowania

Country Status (27)

Country	Link
US (9)	US20170145086A1 (pl)
EP (2)	EP3380522B1 (pl)
JP (4)	JP2019506363A (pl)
KR (2)	KR20250008787A (pl)
CN (3)	CN109089419B (pl)
AU (1)	AU2016361488B2 (pl)
CA (1)	CA3006058A1 (pl)
CL (2)	CL2018001372A1 (pl)
CO (1)	CO2018006461A2 (pl)
DK (1)	DK3380522T5 (pl)
ES (1)	ES2970864T3 (pl)
FI (1)	FI3380522T3 (pl)
HK (1)	HK1254337A1 (pl)
HR (1)	HRP20231578T1 (pl)
HU (1)	HUE064791T2 (pl)
IL (2)	IL259585B2 (pl)
LT (1)	LT3380522T (pl)
MA (1)	MA43308A (pl)
MX (2)	MX2018006385A (pl)
MY (1)	MY197345A (pl)
PL (1)	PL3380522T3 (pl)
PT (1)	PT3380522T (pl)
SA (1)	SA518391659B1 (pl)
SG (1)	SG11201804309PA (pl)
SI (1)	SI3380522T1 (pl)
WO (1)	WO2017091683A1 (pl)
ZA (1)	ZA201803366B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20210340266A1 (en) *	2008-10-09	2021-11-04	Visterra, Inc.	Antibody molecules to april and uses thereof
NL2011406C2 (en)	2013-09-06	2015-03-10	Bionovion Holding B V	Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
US10793571B2 (en)	2014-01-31	2020-10-06	Dana-Farber Cancer Institute, Inc.	Uses of diazepane derivatives
EP3099677A4 (en)	2014-01-31	2017-07-26	Dana-Farber Cancer Institute, Inc.	Diaminopyrimidine benzenesulfone derivatives and uses thereof
NL2014108B1 (en)	2015-01-09	2016-09-30	Aduro Biotech Holdings Europe B V	Altered april binding antibodies.
EP3347021A4 (en)	2015-09-11	2019-07-24	Dana-Farber Cancer Institute, Inc.	CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF
RU2018112953A (ru)	2015-09-11	2019-10-14	Дана-Фарбер Кэнсер Инститьют, Инк.	Ацетамидтиенотриазолодиазепины и пути их применения
MX2018006499A (es)	2015-11-25	2018-08-01	Dana Farber Cancer Inst Inc	Inhibidores de bromodominio bivalentes y usos de los mismos.
FI3380522T3 (fi)	2015-11-25	2024-01-16	Visterra Inc	Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä
JP7749319B2 (ja)	2017-10-10	2025-10-06	アルパインイミューンサイエンシズインコーポレイテッド	Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
AU2019417720A1 (en) *	2018-12-24	2021-07-08	Visterra, Inc.	Methods for identifying epitopes and paratopes
CA3131019A1 (en)	2019-02-22	2020-08-27	Memorial Sloan Kettering Cancer Center	Cd33 antibodies and methods of using the same to treat cancer
CN110522902B (zh) *	2019-09-25	2022-10-11	南京农业大学	一种用于建立慢性肾病模型的组合物及其应用
JP7686000B2 (ja) *	2019-12-24	2025-05-30	ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド	新規抗ＦＧＦＲ２ｂ抗体
IL296358A (en) *	2020-03-13	2022-11-01	Janssen Biotech Inc	Materials and methods for modulating delta chain mediated immunity
EP4146684A2 (en)	2020-05-08	2023-03-15	Alpine Immune Sciences, Inc.	April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
CA3187823A1 (en) *	2020-06-24	2021-12-30	Visterra, Inc.	Antibody molecules to april and uses thereof
WO2022081716A1 (en) *	2020-10-13	2022-04-21	Accubit LLC - Biotechnology	Methods of treating iga nephropathy with thiol-containing molecules
EP4237003A4 (en)	2020-10-28	2025-07-09	Janssen Biotech Inc	COMPOSITIONS AND METHODS FOR MODULATING GAMMA DELTA CHAIN-MEDIATED IMMUNITY
CN112730851B (zh) *	2021-03-31	2021-06-22	南京立顶医疗科技有限公司	一种高灵敏SARS-CoV-2中和抗体的检测方法、检测试剂盒
AU2022269411A1 (en) *	2021-05-04	2023-12-21	Immunorizon Ltd.	Anti-nkg2d antibodies and uses thereof
US20240279310A1 (en)	2021-05-07	2024-08-22	Alpine Immune Sciences, Inc.	Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
KR20240021179A (ko) *	2021-05-14	2024-02-16	더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템	키메라 폴리펩티드 및 사용 방법
TW202342548A (zh)	2022-02-07	2023-11-01	美商威特拉公司	抗獨特型(anti-idiotype)抗體分子及其用途
US20240092921A1 (en)	2022-04-25	2024-03-21	Visterra, Inc.	Antibody molecules to april and uses thereof
KR20250099778A (ko)	2022-10-04	2025-07-02	알파인 이뮨 사이언시즈, 인코포레이티드	자가항체-매개 질환의 치료에 사용하기 위한 돌연변이된 taci-fc 융합 단백질
CN119930816A (zh) *	2023-11-02	2025-05-06	广东菲鹏制药股份有限公司	抗cd39人源化抗体或其抗原结合片段及其应用
WO2026067804A1 (zh) *	2024-09-30	2026-04-02	信立泰(成都)生物技术有限公司	一种抗april抗体或其抗原结合片段及用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS6147500A (ja)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
JPS61134325A (ja)	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
DE3689123T2 (de)	1985-11-01	1994-03-03	Xoma Corp	Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja)	1987-03-18	2000-10-23	エス・ビィ・２・インコーポレイテッド	変性抗体の、または変性抗体に関する改良
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
EP0436597B1 (en)	1988-09-02	1997-04-02	Protein Engineering Corporation	Generation and selection of recombinant varied binding proteins
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8905669D0 (en)	1989-03-13	1989-04-26	Celltech Ltd	Modified antibodies
WO1991000906A1 (en)	1989-07-12	1991-01-24	Genetics Institute, Inc.	Chimeric and transgenic animals capable of producing human antibodies
DE69120146T2 (de)	1990-01-12	1996-12-12	Cell Genesys Inc	Erzeugung xenogener antikörper
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
DK0585287T3 (da)	1990-07-10	2000-04-17	Cambridge Antibody Tech	Fremgangsmåde til fremstilling af specifikke bindingsparelementer
ATE158021T1 (de)	1990-08-29	1997-09-15	Genpharm Int	Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
DE69133557D1 (de)	1990-08-29	2007-03-15	Pharming Intellectual Pty Bv	Homologe rekombination in säugetier-zellen
CA2095633C (en)	1990-12-03	2003-02-04	Lisa J. Garrard	Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en)	1991-03-01	2009-08-12	Dyax Corporation	Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de)	1991-04-10	2008-12-15	Scripps Research Inst	Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (de)	1991-07-08	1993-11-11	Deutsches Krebsforsch	Phagemid zum Screenen von Antikörpern
DK1621554T4 (da)	1992-08-21	2012-12-17	Univ Bruxelles	Immunoglobuliner blottet for lette kæder
CZ294615B6 (cs)	1997-09-12	2005-02-16	Apotech R & D Sa	Léčivo obsahující protilátky reaktivní s polypeptidovým ligandem APRIL pro léčení rakoviny
WO2001060397A1 (en)	2000-02-16	2001-08-23	Genentech, Inc.	Uses of agonists and antagonists to modulate activity of tnf-related molecules
UA74798C2 (uk)	1999-10-06	2006-02-15	Байоджен Айдек Ма Інк.	Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001087977A2 (en)	2000-05-12	2001-11-22	Amgen Inc.	Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP1401870A4 (en)	2001-05-24	2006-04-19	Human Genome Sciences	ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL)
US20070249530A1 (en)	2004-01-29	2007-10-25	Genentech, Inc.	Bcma Polypeptides and Uses Thereof
US8802820B2 (en) *	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
EP1934258B1 (en) *	2005-09-26	2011-03-02	Enzo Life Sciences (ELS) AG	Antibodies against april as biomarkers for early prognosis of lymphoma patients
CN101678106B (zh)	2007-03-27	2013-06-05	津莫吉尼蒂克斯公司	用于治疗自身免疫疾病的BLyS抑制和/或APRIL抑制与免疫抑制剂的组合
JO3076B1 (ar) *	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
EP2203180B1 (en) *	2007-10-22	2012-11-21	Merck Serono S.A.	Single ifn-beta fused to a mutated igg fc fragment
HUE028784T2 (en) *	2008-05-01	2017-01-30	Zymogenetics Inc	Serum levels and use of BLYS / APRIL heterotrimers in diagnostic procedures
US20210340266A1 (en)	2008-10-09	2021-11-04	Visterra, Inc.	Antibody molecules to april and uses thereof
CA2754127C (en) *	2009-03-02	2017-04-18	Stichting Top Institute Pharma	Antibodies against a proliferating inducing ligand (april)
EP2488200A4 (en)	2009-10-14	2013-06-12	Merck Sharp & Dohme	APRIL ANTAGONISTS AND METHOD FOR THEIR USE
US8961967B2 (en) *	2009-11-30	2015-02-24	Janssen Biotech, Inc.	Antibody Fc mutants with ablated effector functions
KR101871008B1 (ko) *	2010-09-16	2018-06-25	발리오팜 아게	항-huTNFR1 항체
JP6072771B2 (ja)	2011-04-20	2017-02-01	メディミューン，エルエルシー	Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
KR101972446B1 (ko)	2011-05-27	2019-04-25	글락소 그룹 리미티드	Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질
DK3424953T3 (en) *	2011-06-06	2020-11-02	Novo Nordisk As	Terapeutiske antistoffer
TWI679212B (zh)	2011-11-15	2019-12-11	美商安進股份有限公司	針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US9243058B2 (en)	2012-12-07	2016-01-26	Amgen, Inc.	BCMA antigen binding proteins
JP2016515120A (ja) *	2013-03-15	2016-05-26	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
NL2011406C2 (en)	2013-09-06	2015-03-10	Bionovion Holding B V	Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
EP3065774B1 (en) *	2013-11-06	2021-05-26	Janssen Biotech, Inc.	Anti-ccl17 antibodies
NL2014108B1 (en)	2015-01-09	2016-09-30	Aduro Biotech Holdings Europe B V	Altered april binding antibodies.
WO2016113368A1 (en)	2015-01-15	2016-07-21	Universite Grenoble Alpes	Anti april (a proliferation-inducing ligand) antibodies and their uses for the prognosis and/or diagnosis of cancer
FI3380522T3 (fi)	2015-11-25	2024-01-16	Visterra Inc	Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä
CN105390742A (zh) *	2015-12-31	2016-03-09	石家庄圣泰化工有限公司	高电压锂离子电池电解液及其制备方法及应用
WO2020144535A1 (en)	2019-01-08	2020-07-16	Aduro Biotech Holdings, Europe B.V.	Methods and compositions for treatment of multiple myeloma
CA3187823A1 (en)	2020-06-24	2021-12-30	Visterra, Inc.	Antibody molecules to april and uses thereof
TW202342548A (zh)	2022-02-07	2023-11-01	美商威特拉公司	抗獨特型(anti-idiotype)抗體分子及其用途
US20240092921A1 (en)	2022-04-25	2024-03-21	Visterra, Inc.	Antibody molecules to april and uses thereof

2016
- 2016-11-23 FI FIEP16810195.4T patent/FI3380522T3/fi active
- 2016-11-23 JP JP2018526763A patent/JP2019506363A/ja not_active Ceased
- 2016-11-23 LT LTEPPCT/US2016/063518T patent/LT3380522T/lt unknown
- 2016-11-23 HU HUE16810195A patent/HUE064791T2/hu unknown
- 2016-11-23 MY MYPI2018000794A patent/MY197345A/en unknown
- 2016-11-23 HR HRP20231578TT patent/HRP20231578T1/hr unknown
- 2016-11-23 US US15/360,145 patent/US20170145086A1/en not_active Abandoned
- 2016-11-23 CN CN201680079727.0A patent/CN109089419B/zh active Active
- 2016-11-23 CA CA3006058A patent/CA3006058A1/en active Pending
- 2016-11-23 KR KR1020247042525A patent/KR20250008787A/ko active Pending
- 2016-11-23 SG SG11201804309PA patent/SG11201804309PA/en unknown
- 2016-11-23 PT PT168101954T patent/PT3380522T/pt unknown
- 2016-11-23 PL PL16810195.4T patent/PL3380522T3/pl unknown
- 2016-11-23 CN CN202410173851.XA patent/CN118027201A/zh active Pending
- 2016-11-23 HK HK18113413.2A patent/HK1254337A1/zh unknown
- 2016-11-23 IL IL259585A patent/IL259585B2/en unknown
- 2016-11-23 ES ES16810195T patent/ES2970864T3/es active Active
- 2016-11-23 EP EP16810195.4A patent/EP3380522B1/en active Active
- 2016-11-23 DK DK16810195.4T patent/DK3380522T5/da active
- 2016-11-23 WO PCT/US2016/063518 patent/WO2017091683A1/en not_active Ceased
- 2016-11-23 AU AU2016361488A patent/AU2016361488B2/en active Active
- 2016-11-23 CN CN202410173854.3A patent/CN118420760A/zh active Pending
- 2016-11-23 MA MA043308A patent/MA43308A/fr unknown
- 2016-11-23 EP EP23200975.3A patent/EP4285923A3/en active Pending
- 2016-11-23 SI SI201631788T patent/SI3380522T1/sl unknown
- 2016-11-23 KR KR1020187017534A patent/KR102747820B1/ko active Active
- 2016-11-23 MX MX2018006385A patent/MX2018006385A/es unknown
- 2016-11-23 IL IL313508A patent/IL313508A/en unknown
2018
- 2018-05-21 ZA ZA2018/03366A patent/ZA201803366B/en unknown
- 2018-05-22 CL CL2018001372A patent/CL2018001372A1/es unknown
- 2018-05-23 MX MX2024010175A patent/MX2024010175A/es unknown
- 2018-05-23 SA SA518391659A patent/SA518391659B1/ar unknown
- 2018-06-22 CO CONC2018/0006461A patent/CO2018006461A2/es unknown
- 2018-12-07 US US16/212,957 patent/US10385123B2/en active Active
2019
- 2019-06-28 US US16/456,810 patent/US20190330326A1/en not_active Abandoned
2020
- 2020-06-10 US US16/898,024 patent/US10954296B2/en active Active
- 2020-06-25 US US16/912,131 patent/US10968270B2/en active Active
- 2020-06-25 US US16/912,085 patent/US10981982B2/en active Active
- 2020-10-20 US US17/074,857 patent/US11136385B2/en active Active
2021
- 2021-08-16 JP JP2021132222A patent/JP7029018B2/ja active Active
- 2021-08-31 US US17/463,319 patent/US12091451B2/en active Active
2022
- 2022-02-17 JP JP2022022801A patent/JP2022068288A/ja not_active Withdrawn
2024
- 2024-01-30 CL CL2024000276A patent/CL2024000276A1/es unknown
- 2024-03-19 JP JP2024043460A patent/JP2024073611A/ja active Pending
- 2024-07-31 US US18/790,750 patent/US20250066464A1/en active Pending

Also Published As

Publication number	Publication date
AU2016361488B2 (en)	2022-12-22
US20190092851A1 (en)	2019-03-28
CN118027201A (zh)	2024-05-14
BR112018010673A8 (pt)	2019-02-26
MA43308A (fr)	2018-10-03
WO2017091683A8 (en)	2022-12-15
KR20250008787A (ko)	2025-01-15
NZ782617A (en)	2025-06-27
ES2970864T3 (es)	2024-05-31
JP2022068288A (ja)	2022-05-09
US20200317770A1 (en)	2020-10-08
RU2018122452A (ru)	2019-12-25
SA518391659B1 (ar)	2022-12-13
ZA201803366B (en)	2025-09-25
AU2023201698A1 (en)	2023-04-20
US20250066464A1 (en)	2025-02-27
KR20180091849A (ko)	2018-08-16
US20210032324A1 (en)	2021-02-04
BR112018010673A2 (pt)	2018-11-13
EP4285923A3 (en)	2024-03-06
CN118420760A (zh)	2024-08-02
EP3380522B1 (en)	2023-11-08
HUE064791T2 (hu)	2024-04-28
US20190330326A1 (en)	2019-10-31
CN109089419B (zh)	2024-03-01
RU2018122452A3 (pl)	2020-05-13
HK1254337A1 (zh)	2019-07-19
MX2024010175A (es)	2024-08-27
MY197345A (en)	2023-06-14
US10954296B2 (en)	2021-03-23
DK3380522T3 (da)	2024-01-22
KR102747820B1 (ko)	2024-12-27
CL2024000276A1 (es)	2024-08-30
US20200331995A1 (en)	2020-10-22
US10968270B2 (en)	2021-04-06
US20220235124A1 (en)	2022-07-28
IL313508A (en)	2024-08-01
IL259585A (en)	2018-07-31
EP4285923A2 (en)	2023-12-06
IL259585B1 (en)	2024-07-01
FI3380522T3 (fi)	2024-01-16
JP2024073611A (ja)	2024-05-29
SI3380522T1 (sl)	2024-02-29
MX2018006385A (es)	2019-09-11
JP2021184740A (ja)	2021-12-09
US20200299376A1 (en)	2020-09-24
US12091451B2 (en)	2024-09-17
PT3380522T (pt)	2024-02-14
HRP20231578T1 (hr)	2024-03-15
IL259585B2 (en)	2024-11-01
JP2019506363A (ja)	2019-03-07
AU2016361488A1 (en)	2018-06-14
JP7029018B2 (ja)	2022-03-02
LT3380522T (lt)	2024-02-26
WO2017091683A1 (en)	2017-06-01
SG11201804309PA (en)	2018-06-28
NZ742879A (en)	2025-06-27
NZ782606A (en)	2025-06-27
EP3380522A1 (en)	2018-10-03
CA3006058A1 (en)	2017-06-01
CO2018006461A2 (es)	2018-08-31
DK3380522T5 (da)	2024-09-30
US10385123B2 (en)	2019-08-20
US10981982B2 (en)	2021-04-20
CN109089419A (zh)	2018-12-25
US20170145086A1 (en)	2017-05-25
CL2018001372A1 (es)	2018-11-23
US11136385B2 (en)	2021-10-05

Publication	Publication Date	Title
PL3380522T3 (pl)	2024-03-25	Cząsteczki przeciwciał wobec april i ich zastosowania
IL259987A (en)	2018-07-31	Antibody molecules to pd-1 and uses thereof
IL269534A (en)	2019-11-28	Chimeric molecules and uses thereof
PL3383916T3 (pl)	2023-06-12	Przeciwciała anty-cd73 i ich zastosowania
IL257324A (en)	2018-03-29	Antibody against glypican-3 and application thereof
PL3280441T3 (pl)	2022-02-21	Przeciwciała przeciwko sortilinie i sposoby ich stosowania
IL255949A (en)	2018-01-31	Antibodies against ox40 and uses thereof
IL262095A (en)	2018-11-29	Anti-pacap antibodies and uses thereof
PL3258951T3 (pl)	2020-07-27	Przeciwciała anty-pvrig i sposoby ich zastosowania
KR102162129B9 (ko)	2023-02-08	항-갈렉틴-9 항체 및 이의 용도
PL4234581T3 (pl)	2026-01-26	Przeciwciała terapeutyczne i ich zastosowania
IL256416B (en)	2021-12-01	Multispecific antigen-binding molecules and uses thereof
ME03558B (me)	2020-07-20	Molekuli anti-lag-3 antiтela i njihove upotrebe
IL246693B2 (en)	2023-03-01	Antibody molecules to tim-3 and uses thereof
PL3148579T3 (pl)	2021-07-19	Przeciwciała anty-gitr i sposoby ich zastosowania
PL3265448T3 (pl)	2022-04-25	Proleki riluzolu i ich zastosowanie
DK3303395T3 (da)	2020-01-27	Anti-cd40-antistoffer og anvendelser deraf
PL3268470T3 (pl)	2021-06-14	Polipeptydy transpozazy i ich zastosowania
PL3274370T3 (pl)	2020-05-18	Przeciwciała anty-ceacam6 i ich zastosowania
HUE054339T2 (hu)	2021-08-30	CD73-ra specifikus kötõmolekulák és alkalmazásaik
DK3265575T3 (da)	2021-05-31	Cd20-bindende molekyler og anvendelser deraf
PL3402821T3 (pl)	2024-03-04	Przeciwciało wiążące psma i jego zastosowania
IL271398A (en)	2020-01-30	Anti-l1-cam antibodies and uses thereof
IL262251B1 (en)	2023-05-01	New anti-sirpa antibodies and their therapeutic applications
PL3359563T3 (pl)	2020-03-31	Receptory antygenów i ich zastosowania